“A new study led by researchers at Boston Medical Center (BMC) indicates that variations in opioid receptor genes are associated with more severe neonatal abstinence syndrome (NAS) in newborn babies. The findings, published online in Drug & Alcohol Dependence, could help lead to the development of individualized treatment plans tailored to each infants’ risk of requiring medication to curb their NAS symptoms, which could help improve these patients’ outcomes and reduce how long some stay in the hospital.
NAS is present in newborn babies who have been exposed to opioids during pregnancy. While some infants require no medication to curb their symptoms after they are born, others may require two or more medications and weeks of hospitalization before they can be discharged. Nearly one in five women in the US now take an opioid medication at some point during their pregnancy, both by prescription and illicit opioids, which has contributed to a tripling in the rate of NAS over the past decade.
“In adults, we know that at least 50 percent of one’s risk for opioid dependence is genetic, which is why it would make sense that infants respond differently to opioid medication exposure,” said Elisha Wachman, MD, a neonatologist at BMC and who served as the study’s lead author.
The multi-center study involved the examination of 86 pairs of full-term, opioid-exposed newborns and their mothers who were taking prescribed methadone or buprenorphine for at least 30 days prior to delivery. DNA samples were collected from all participants and baseline characteristics about the infants. The infants were scored every 3-4 hours with a modified Finnegan NAS scale and were treated according to institutional NAS treatment protocols. Length of hospital stay (LOS) and need for treatment with two or more medications were chosen to reflect the overall severity of NAS.
Source: Eurekalert.org – August 25, 2015